Management speak of optionality BOT definitely not short of that in house we have two leading candidates BTX 1503 (moderate to severe acne) and BTX1801 (Antimicrobial). 1503 the bigger market but 1801 faster to market. Also possible other applications of SB (hands, feet etc)
"Botanix intends to leverage a range of existing US Food and Drug Administration (FDA) programs (e.g.Qualified Infection Disease Product, Fast Track and Limited Population Pathway for Antimicrobial andAntifungal Drugs status) to accelerate BTX 1801 clinical development, reduce clinical costs and increasethe exclusivity period."
Looking forward to management guidance on what the next product will be.
BOT - Anything but charting, page-8896
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.8¢ | $1.949M | 5.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2985 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 420471 | 4 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |